- Open Access
Autism-associated CHD8 deficiency impairs axon development and migration of cortical neurons
Molecular Autism volume 9, Article number: 65 (2018)
Mutations in CHD8, chromodomain helicase DNA-binding protein 8, are among the most replicated and common findings in genetic studies of autism spectrum disorder (ASD). The CHD8 protein is believed to act as a transcriptional regulator by remodeling chromatin structure and recruiting histone H1 to target genes. The mechanism by which deficiency of CHD8 causes ASD has not been fully elucidated.
We examined the expression of CHD8 in human and mouse brains using both immunohistochemistry and RNA in situ hybridization. We performed in utero electroporation, neuronal culture, and biochemical analysis using RNAi to examine the functional consequences of CHD8 deficiency.
We discovered that CHD8 is expressed highly in neurons and at low levels in glia cells in both humans and mice. Specifically, CHD8 is localized predominately in the nucleus of both MAP2 and parvalbumin-positive neurons. In the developing mouse brain, expression of Chd8 peaks from E16 to E18 and then decreases significantly at P14 to adulthood. Knockdown of Chd8 results in reduced axon and dendritic growth, disruption of axon projections to the contralateral cortex, and delayed neuronal migration at E18.5 which recovers by P3 and P7.
Our findings indicate an important role for CHD8 in dendritic and axon development and neuronal migration and thus offer novel insights to further dissect the underlying molecular and circuit mechanisms of ASD caused by CHD8 deficiency.
Autism spectrum disorder (ASD) is a group of clinically and molecularly heterogeneous neurodevelopmental conditions characterized by social communication deficits and restricted, repetitive behaviors [1, 2]. Genetic etiology has been implicated in approximately 20% of ASD patients. More than 70 genes or genomic loci have been confirmed as causative, and hundreds are considered strong candidates [3,4,5,6,7,8,9,10,11,12]. Of these, mutations in CHD8 are among the most replicated and commonly identified genetic findings [6, 7, 13, 14].
CHD8 is a member of the chromodomain helicase DNA-binding protein family, which functions as an ATP-dependent chromatin remodeling factor and plays important roles in chromatin dynamics, transcription, and cell survival . CHD8 is initially identified as a negative regulator of the Wnt–catenin signaling pathway through promoting the association of β-catenin and histone H1 and forming a trimeric complex on chromatin [16,17,18]. Accordingly, Wnt–β-catenin signaling was downregulated in Chd8 mutant mice . Homozygous deletion of Chd8 in mice results in early embryonic lethality as a consequence of massive apoptosis in some lines of mutant mice [19, 20]. Haploinsufficiency of CHD8 causes abnormal activation of RE-1 silencing transcription factor (REST), which suppresses the transcription of many neuronal genes. Moreover, CHD8 interacts physically with REST in the mouse brain . Knockdown of Chd8 by RNAi during cortical development results in defective neural progenitor proliferation, differentiation, and enhanced migration [18, 22]. Deficiency of Chd8 in mice also alters synaptic transmission in striatal circuitry and results in functional over-connectivity in cortical networks . Interestingly, a recent report also shows sexually dimorphic phenotypes related to abnormal neuronal excitation, enhanced inhibitory synaptic transmission and neuronal firing, and gene dysregulation in a new line of Chd8 mutant mice . Conditional knockout of Chd8 in oligodendrocytes results in defective myelination in mice . However, whether CHD8 deficiency affects axonal growth has not been studied.
Here, we report that CHD8 is specifically expressed in both excitatory and inhibitory neurons and to a lesser extent in GFAP+ astrocytes of cerebral cortex in human and mouse brains. Similar to a previous report, we found that the expression of Chd8 peaks during embryonic development and decreases to relatively low levels postnatally in mouse brains . Chd8 deficiency in neocortex by RNAi using in utero electroporation resulted in delayed migration of cortical neurons and impaired dendritic and axonal growth. Our findings provide additional insights into the molecular and circuitry mechanisms underlying ASD caused by CHD8 deficiency. Defective axonal development may support a mechanism underlying the abnormal long distance connectivity reported in neuroimaging studies of ASD in humans.
Immunostaining of human brain sections
For light microscopic immunohistochemistry (IHC), human brain sections (30 μm) were incubated in 0.01 M phosphate-buffered saline (PBS) supplemented with 3% hydrogen peroxide for 10 min to block endogenous peroxidase and then in a blocking buffer containing 5% BSA/10% normal goat serum/0.25% Triton X-100 for 60 min at room temperature to prevent nonspecific staining. Following this, IHC was conducted on these free-floating sections and staining was visualized with a standard ABC Elite kit (Vector Labs).
For confocal microscopic double-labeling immunofluorescence, brain sections were incubated in the blocking buffer for 60 min at room temperature and then in a solution containing primary antibodies from different species simultaneously for one night at 4 °C. After washing, sections were incubated with appropriate secondary antibodies from Alexa Fluor series (Invitrogen, USA) for 45 min at 37 °C and then counterstained with Hoechst 33342 (1:5000; #C10022, Beyotime) for 15 min at room temperature to identify cellular nuclei. After mounting the sections, we observed them under a fluorescent confocal microscope (A1R Nikon).
Primary antibodies used were as follows: anti-CHD8 (1: 500; catalog #A301-225A; Bethyl Laboratories, Inc.), anti-GFAP (1:1000, catalog #MAB3402, Millipore), anti-MAP2 (1:2000, catalog #M9942, Sigma), anti-parvalbumin (Pvalb) (1:500, catalog #MAB1572, Millipore), and anti-DCX antibodies (1:200, catalog #Sc-8066, Santa Cruz).
For Nissl staining, Neuro Trace 500/525 green fluorescent Nissl stain (N21480) was bought from Thermo Fisher Scientific and used according to the manufacture’s instruction.
Confocal microscopic double-labeling immunofluorescence of mouse brain slices
Mice were sacrificed by cervical dislocation at postnatal day 3 (P3) or P7. Their brains were removed and fixed in 4% (wt/vol) paraformaldehyde (PFA) overnight. After sequential dehydration in 15% and 30% sucrose at 4 °C, 50-μm coronal brain sections were cut with a cryostat, fixed in 4% PFA for 20 min at 4 °C, washed three times with PBS, blocked with 5% BSA and 0.3% Triton X-100 in PBS for 1 h at room temperature, and then incubated with rabbit anti-GFP (1:1000, catalog #A11122, Invitrogen) primary antibody overnight at 4 °C. The rinsed sections were then incubated with Alexa 488-conjugated goat anti-rabbit secondary antibody (1:3000; catalog #A-11122; Invitrogen) for 2 h at 37 °C. For endogenous CHD8 and NeuN immunostaining, sections were incubated with anti-CHD8 antibody (1: 500; catalog #A301-225A; Bethyl Laboratories, Inc.) and anti-NeuN antibody (1:500; catalog # MAB377; Millipore).
Cultured neurons were fixed with 4%PFA and then immunostained with primary antibodies against GFAP (1:1000, catalog #MAB3402, Millipore), MAP2 (1:2000, catalog #M9942, Sigma), and Tau1 (1:3000, catalog #MAB3420, Millipore) overnight at 4 °C. After washing, sections were then incubated with Alexa 488-conjugated goat anti-rabbit secondary antibody (1:3000, catalog #A-11122, Invitrogen) and Alexa 568-conjugated goat anti-mouse secondary antibody (1:2000, catalog #A-11004, Invitrogen) for 2 h at 37 °C.
RNA extraction and real-time PCR
Forebrain tissues from embryonic or postnatal mice (C57BL/6) at different developmental stages (E16, E18, P0, P7, P14, P21, and adult) were used for RNA extraction. Mice were anesthetized with sodium pentobarbital and sacrificed via cervical dislocation, and brain tissues were quickly removed, dissected on ice, and homogenized with TRIzol Reagent (Invitrogen) at 4 °C. RNA was extracted according to the recommendations of the manufacturer, the final RNA pellet was suspended in diethylpyrocarbonate (DEPC)-treated water, and 2 μg of total mRNA was further subjected to reverse transcription using oligo (dT) primers and Moloney murine leukemia virus (M-MLV) transcriptase (Invitrogen). Real-time PCR was done with a LightCycler 480 Real-Time PCR System (Roche) according to the manufacturer’s instructions. Starting RNA levels were quantified by using GAPDH as the external standard. Primer sets were chosen from Primerbank, and gene sequences are available from the GenBank database. The primer sequences to examine the mRNA expression of mouse Chd8 were as follows: forward, 5′-AAGCCCAGGTAACTCAAC-3′; reverse, 5′-TTCACATCGTCGGCGTCT-3′; GAPDH: forward, 5′-GGTTGTCTCCTGCGACTTCA-3′; reverse, 5′-CCACCACCCTGTTGCTGTAG-3′. The primers were synthesized by Invitrogen.
RNA in situ hybridization
RNA in situ hybridization on the mouse brain sections was performed with digoxigenin (DIG)-labeled RNA probes. Full-length cDNA of Chd8 was amplified with specific PCR primers and cloned into a pGEM-T easy vector (Promega) to generate an antisense probe for Chd8. The DIG-labeled antisense probes were synthesized by in vitro transcription using SP6 RNA polymerase. Mice of different developmental stages were perfused with 4% PFA, and fixed brains were sectioned into 20-μm slices using a cryostat. RNA in situ hybridization was performed as described previously . Brain sections were hybridized for 18 h at 60 °C. The hybridization signal was detected with anti-DIG–alkaline phosphatase Fab fragments (Roche) and nitro blue tetrazolium chloride (NBT) plus 5-bromo-4-chlor-indolyl-phosphate (BCIP) as color reaction substrates.
Human CHD8 cloning and mouse shRNA construct preparation
Human CHD8 cDNA (CHD8, variant 1 - HaloTag® human ORF in pFN21A) was purchased by Promega (catalog: FHC12740). PCR products were cloned into the pCAGGS-IRES-EGFP vector . Oligonucleotides targeting different sequences of mouse Chd8 cDNA and a scrambled control oligonucleotide were designed, synthesized, and cloned into pSuper-basic (Oligoengine). The 21-bp target sequences were as follows: shRNA#1, 5′-GCT GGT GGA CTT GGT ATT AAT-3′; shRNA#2, 5′-GCT GCT GAT ACC TGT ATT ATC-3′; shRNA#3, 5′-GCT ACA AGA GAG AAC AAA TGA-3′; and shRNA-scramble, 5′-TTC TCC GAA CGT GTC ACG T-3′. All constructs were verified by DNA sequencing.
Western blot analysis
For the analysis of the expression of CHD8 in the developing mouse cortex, cortices were dissected and homogenized as previously described . For knockdown and rescue experiments, electroporated cortical neurons were cultured for 3–7 days and lysed in 1× protein loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% 2-ME, and 0.1% bromophenol blue). All protein samples were separated by 10% SDS-polyacrylamide gel electrophoresis (Bio-Rad) and blotted onto PVDF membrane (Millipore). Membranes were blocked with 5% non-fat milk in 0.05% Tween 20 at room temperature for 1 h and probed with rabbit anti-CHD8 (Bethyl Laboratories, Inc.), HRP-coupled mouse anti-actin (Santa Cruz Biotechnology) antibodies. The secondary antibody used for CHD8 was goat anti-rabbit IgG coupled to HRP (Santa Cruz biotechnology). Bands were visualized by enhanced chemiluminescence (TIANGEN). Band intensities were measured with ImageJ Software.
Primary neuron culture and electroporation
Primary cortical neurons were prepared from brains of P0 C57 mice as described previously . Before plating, neurons suspended in transfection medium (200 μl) were mixed with 1 μg pCAG-EGFP and 3 μg shRNA for immunocytochemistry. Then, neurons were transferred into a 2.0-mm electroporation cuvette (Fisher) and transfected by electroporation using the Amaxa Nucleofector apparatus.
In utero electroporation
In utero electroporation was performed as described previously with a few modifications . Briefly, pregnant mice at E14.5 were anesthetized with 0.7% sodium pentobarbital at a dose of 10 μl/g and subjected to abdominal incision to expose the uterus. For different experiments, a mixture of GFP, RNAi, and/or rescue constructs was prepared. Plasmids (about 1 μl) with 0.05% Fast Green (Sigma) were injected into the lateral ventricle of embryos through a glass micropipette. Electrical pulses were then delivered to embryos by gently clasping their heads with forcep-shaped electrodes connected to an ECM-830 square-pulse generator (BTX). Five 50-ms pulses of 30 V were applied at 1-s intervals. Uterine horns were repositioned in the abdominal cavity, and the abdominal wall and the skin were sutured. Postsurgery animals were maintained in a warm animal room (25 °C) with plenty of water and food. At different developmental stages, mice were perfused transcardially with 0.9% saline followed by 4% PFA in 0.1 M phosphate buffer (PB; pH 7.4), and the brains were removed and fixed in 4% PFA for another 24 h. Fixed brains were cryoprotected with 30% sucrose and then sectioned using a cryostat.
Image acquisition and quantification
Images were obtained with a Nikon A1R inverted confocal microscope with × 20 (numerical aperture, 0.7) objectives. Each image was a composite constructed from a series of images taken throughout the z aspect of the neuron. Images of isolated cells or cortical neurons in regions with a low density of GFP transfected cells were chosen for illustration, and three-dimensional (3D) reconstructions were made to trace dendritic or axonal arbors for measurement of total dendritic or axonal length. Neurolucida software (MBF Bioscience) was used to generate tracings to measure neurite lengths. Sholl analysis, a quantitative analysis by counting the number of neurite intersections of concentric circles of gradually increased radius centered at the cell body, was performed with Neurolucida Explorer (MBF Bioscience). Image acquisition and data analysis were performed in a double-blind manner.
For all statistical analyses, experimenters were blinded for genotypes of mice and the treatments of the animals or cells. Data are presented as mean ± SEM. The paired or unpaired Student’s t test, one-way ANOVA with Dunnett’s post hoc tests or Bonferroni’s tests, or two-way ANOVA with Bonferroni post hoc tests were used for data analyses by SPSS 13.0 software. Statistical significance was defined as P < 0.05.
Except in utero electroporation, for which ICR mice were used, all other experiments were performed in C57BL/6 J mice. Pregnant mice undergoing in utero electroporation were individually housed in plastic cages, and when they delivered, they were housed with their pups.
Human brain tissues
Frozen postmortem brain tissues of Brodmann 19 region from a 6-year-old child was obtained from the NIH human brain tissue bank at the University of Maryland (http://www.medschool.umaryland.edu/btbank/). The postmortem time was 19 h.
CHD8 is predominantly expressed in neurons of human cerebral cortex
To probe the function of CHD8 and its pathophysiology underlying ASD, we first examined the expression pattern of CHD8 in a human brain sample. We performed immunohistological analysis using postmortem brain tissue (Brodmann 19) of a 6-year-old child. Strong staining of CHD8 was revealed in cerebral cortex (Fig. 1a). CHD8 was highly expressed in Neuro Trace Nissl stain-positive neurons but to a lesser extent in GFAP-positive glia cells (Fig. 1b, c). Consistent with the known function of CHD8 as a chromatin regulator, immunofluorescent staining showed that CHD8 was predominantly localized in the nucleus (Fig. 1b, f). Co-staining of CHD8 and neuronal markers showed that CHD8 was expressed in both MAP2-positive excitatory neurons (Fig. 1d) and parvalbumin (Pvalb)-positive interneurons (Fig. 1e). Moreover, CHD8 was expressed in Doublecortin (DCX)-positive neuronal precursor cells and immature neurons (Fig. 1f), which is consistent with the early onset of clinical manifestations in patients with CHD8 mutations.
Chd8 is highly expressed in the developing mouse brain
Next, we examined the expression pattern of Chd8 in the mouse brain at different developmental stages. Quantitative real-time mRNA expression analysis (qRT-PCR) (Fig. 2a) revealed that Chd8 was detectable in neocortex from E16 to adulthood. The peak of the expression is at E18 and then markedly decreases at P7 and gradually declines to very low levels at adulthood. This expression pattern in neocortex was also confirmed at the protein level by western blot analysis (Fig. 2b, c). To examine the temporal and spatial expression pattern of Chd8 in the developing brain, we performed RNA in situ hybridization on mouse brain sections. Chd8 mRNA was most abundant in embryonic brain and then gradually reduced after birth, consistent with the results from the qRT-PCR and western blot analyses. Specifically, Chd8 mRNA was present in the sub-plate (SP) and proliferative zones of the cortical wall (the ventricular zone [VZ] and the subventricular zone [SVZ]) at E16 and P0 and in the cortical plate (CP) of the cerebral cortex, hippocampus, striatum, cerebellum, and olfactory bulb from P3 to P7, a developmental period with extensive outgrowth and elaboration of dendrites and axons (Fig. 2d, e). The cellular and subcellular localizations of CHD8 in developing mouse brains and cultured neurons were also examined by immunostaining with neuronal cell markers. Consistent with the results in human cerebral cortex, mouse CHD8 was expressed in the neuronal nucleus, with a pattern similar to that of NeuN in neocortex and hippocampus in P3 mouse (Fig. 3a–c). CHD8 expression in neurons and glia cells was also confirmed by western blot analysis of cultured DIV3 neurons and glia cells of mice (Fig. 3d). However, the expression of CHD8 in glia cells was significantly lower than that in neurons. Taken together, the expression analyses of both human and mouse brains imply important roles for CHD8 during the development of cerebral cortex.
CHD8 regulates neuronal morphogenesis in vitro
Altered short- and long-distance functional connectivity has been reported frequently in brains of human ASD patients by neuroimaging studies [29, 30]. Impaired dendritic development has been reported in numerous mouse models of ASD [31,32,33]. However, few studies have examined axonal development in ASD animal models. We therefore examined whether Chd8 deficiency affects the development of both dendritic morphology and callosal axon growth during development using a shRNA approach. We designed three shRNA constructs that were targeting to Chd8 and tested the efficiency in both cultured neurons and in vivo in mouse brains. Compared with the scramble shRNA construct, all shRNAs resulted in a significant decrease in the expression of CHD8 protein in cultured neurons, and among them, shRNA#1 had the highest efficiency (Fig. 4a). The efficacy of the shRNA constructs was confirmed in vivo in mouse brain (Fig. 4b). We also validated the rescued constructs against shRNA-mediated knockdown of mouse Chd8 in transfected neurons in vitro (Additional file 1: Figure S1). To examine axonal growth, we co-transfected dissociated DIV0 mouse cortical neurons with plasmids encoding GFP and shRNA constructs by electroporation and then plated them to allow the neurons to grow in culture medium for 3 days (DIV3). We used Tau1 as an axon-specific marker. We found that depleting CHD8 significantly decreased total axon growth (Fig. 4c, d). However, co-expression of human CHD8 protein (hCHD8) that is shRNA#2-resistant was able to rescue the total axon length defects caused by shRNA#2 construct (Fig. 4c–e; Additional file 1: Figure S1). We next examined the effects of Chd8 knockdown on dendritic outgrowth and branching in vitro. Control neurons were transfected at DIV0 with GFP plus a non-targeting shRNA construct (shRNA-scr). Seven days later, we analyzed the data after staining cells with the somatodendritic marker MAP2 (Fig. 4f). The total and mean dendrite length were significantly reduced in neurons expressing both shRNA#1 and shRNA#2 constructs compared to those expressing shRNA-scr (Fig. 4g). It is worth noting that the intersections were more affected by shRNA#1 construct than by shRNA#2 construct (Fig. 4h). This appears to be consistent with the more significant reduction of Chd8 after shRNA#1 treatment than that of shRNA#2. The effects of shRNA#2 were rescued by co-transfecting shRNA2-resistant hCHD8 (Fig. 4i, j). These results indicate CHD8 is required for both axonal and dendritic development.
CHD8 is essential for neurite development in vivo
To test whether Chd8 deficiency has effects on mouse brains in vivo, we used the shRNA#2 construct for this experiment because of the feasibility of conducting rescue experiments as demonstrated in vitro. At P3, mouse pups electroporated with scrambled shRNA had callosal axons originating from the electroporated neurons that crossed the midline and formed and arborized dense projections to the contralateral side of cerebral cortex, and the axon bundles were restricted to the corpus callosum (CC) (Fig. 5a–c, j, k). In contrast, in mice transfected with the Chd8 shRNA#2 construct, the axon terminals were barely visible in the contralateral cerebral cortex, indicating significantly retarded axon growth and elongation (Fig. 5d–f, j, k). Co-transfection of the shRNA#2-resistant hCHD8 construct successfully rescued these defects (Fig. 5g–k). These findings suggest that reduced expression of Chd8 in callosal projection neurons impairs axon growth and branching in vivo.
To assess the impact of Chd8 knockdown on the development of neuronal dendrites, we performed morphological analysis of the layer II/III pyramidal neurons of somatosensory cortex 1 (S1). The layer II/III pyramidal neurons of S1 constitute the main excitatory neuronal subtypes in the neocortex and typically having an apical dendrite that branches out in an apical tuft that terminates in layer I . Most scrambled shRNA-transfected neurons displayed a typical polarized dendritic arbor (Fig. 6a, b). In contrast, the Chd8 shRNA significantly decreased the secondary branches and the total number and mean length of dendritic branches in neurons (Fig. 6c, d). The complexity of dendrites was also significantly decreased by Chd8 shRNA constructs, revealed by Sholl analysis (Fig. 6e). These results indicated that CHD8 plays an essential role in neuronal morphogenesis in the mouse cerebral cortex.
CHD8 deficiency impairs the migration of cortical neurons
Because of the expression of CHD8 in DCX-positive neural precursors, we examined whether its deficiency affected the radial migration of cortical neurons. The shRNA and EGFP constructs were co-electroporated into the developing mouse cortex at E14.5 using in utero electroporation (IUE) as previously described , and the distribution of EGFP-labeled cells in neocortex was examined at E18.5. While the majority of the EGFP-positive cells (76.8 ± 0.6%) migrated to the upper cortical plate (CP) when scrambled shRNA was co-expressed, only a small percentage of EGFP cells were observed in the upper CP when the Chd8 shRNA constructs were co-expressed (shRNA#1, 10.1 ± 1.2%; shRNA#2, 14.4 ± 0.9%;) and the majority of labeled cells remained in the VZ/SVZ (Fig. 7a, b). Interestingly, the number of EGFP-positive cells that reached the upper CP was comparable between shRNA construct and scrambled controls at P3 and P7 (Fig. 7c–f). Accordingly, there are a comparable number of neurons that remained in the white matter (WM) and layers IV–VI. Together, these results indicate that deficiency of Chd8 could cause a delay in radial migration of cortical neurons during early embryonic development, but this normalizes during postnatal development.
Genetic studies have provided strong evidence supporting an etiological role for genes encoding the proteins of epigenetic machinery in ASD [10, 34]. CHD8 is one of the most prominent and repeatedly reported genes in this class . In contrast to the well-characterized synaptic genes that are also strongly implicated in ASD, the molecular pathogenesis of ASD caused by deficiency of epigenetic machinery proteins such as CHD8 remains to be thoroughly investigated. Through studies of Chd8 deficiency in cultured rodent neurons or mutant mice by different experimental approaches, several groups have provided initial evidence supporting a causal link between a deficiency of CHD8 and neural cell proliferation, synaptic function, myelination, and ASD-like behaviors. The major findings from these studies and the current study are summarized in Table 1 [18, 20,21,22,23,24,25, 35, 36]. The results among these studies are not always consistent; in some cases, opposite findings are reported. For example, the decreased proliferation of neural progenitor cells is associated with Chd8 deficiency using RNAi by in utero electroporation but the increased proliferation was reported in mice with germline mutation. Interestingly, a recent study of a new line of Chd8 mutant mice reports sexually dimorphic phenotypes at molecular, synaptic function, and behavioral levels . Another report also finds that Chd8 deficiency, selectively in oligodendrocytes but not in neurons, results in myelination defects in mice. Similarly, different ASD-related behavioral phenotypes are also observed among different lines of Chd8 mutant mice. Unfortunately, behavioral phenotypes have not been examined in oligodendrocyte-specific Chd8 deficiency mice. Whether these discrepancies are due to different Chd8 mutations in these lines of mutant mice or other experimental procedure-related issues are not immediately clear. Future studies of performing the experiments in parallel in different lines Chd8 mutant mice are warranted.
In this study, we have shown that CHD8 is expressed at high level in both NeuN-positive mature neurons and parvalbumin-positive interneurons and to a lesser extent in GFAP-positive astrocytes in human cerebral cortex. A previous study has found that the peak expression of CHD8 is between 13 and 19 weeks in the dorsolateral prefrontal cortex and 10–13 weeks of medial prefrontal cortex in humans . In the developing mouse brain, we find that Chd8/CHD8 expression peaks around embryonic days 16–18 and decreases to much lower levels by P21 by both mRNA and protein analyses. This finding is largely consistent with the reports of the development-specific expression of CHD8 in previous studies [18, 20, 22]. However, there are differences in the experimental designs among these studies. In our study, the Chd8 expression study by real-time RT-PCR, RNA in situ hybridization, and western blot are performed in tissues from E16 day embryos to adult brains. In study by Nishiyama et al., the expression is examined by western blot and whole mount in situ in cells or tissues from embryonic stem (ES) cells as well as from E7.5 day embryos to adult mice . The expression is high in ES and early embryonic stage, but a definitive peak is not seen. In other study by Platt et al. , real-time RT-PCR, western blot, and RNA in situ hybridization are used to examine the Chd8 expression in brain tissues from E10 day embryos to adult mice. The highest expression is seen around E10–11 day embryos. In the study that the expression is examined in brain tissues from E12 to P2, the highest expression is at E12 . With the caveats in the experimental designs, it is possible that the peak expression of Chd8 is before E7 day because homozygous Chd8 mutant are arrested before gastrulation because of massive apoptosis .
Consistent with previous report , we have also shown the evidence supporting the role of CHD8 in dendrite development of pyramidal neurons. The loss of CHD8 inhibits dendritic outgrowth and branch formation. In contrast to other reports, we have shown for the first time from both in vitro and in vivo studies that deficiency of CHD8 in developing mouse neurons inhibits axon growth and branch formation and results in a disruption of callosal axon projections to the contralateral cortex. The effect of CHD8 deficiency on the growth of axons is consistent with the report of dysregulation of genes implicated in axonal development in IPSC-derived neurons from human CHD8 patients [36, 37]. Together, our data demonstrate that CHD8 is important for normal dendritic and axonal development and that dysregulation of the process may contribute abnormal neuronal connectivity.
The peak expression in early and middle fetal development suggests a functional role of CHD8 in cortical development. Indeed, we found that Chd8 knockdown results in a significant delayed migration of newborn cortical neurons examined at E18.5. This is opposite to the enhanced migration reported by Durak et al. using the similar approach but at different time points during the fetal development . We performed in utero electroporation for Chd8 knockdown at E14.5 and analyzed the cell migration at E18.5 while Durak et al. performed the in utero electroporation at E14 and analyzed at E16. Whether the different timing of CHD8 deficiency is responsible for the observed phenotypic differences remains to be determined. Because transcriptional regulation implicated in cortical development is dynamic and epigenetically modulated , it is also conceivable that CHD8 may have different roles at the different stages of fetal brain development. Interestingly, the delayed neuronal migration associated with knockdown of Chd8 in our study is recovered at P3 and P7. This may suggest a catch-up period of the CHD8-deficient neurons after E18.5 days. Taken together, our findings support that CHD8 plays a critical role in migration of mitotic neurons as well as both dendritic and axonal growth in neocortex.
Human patients with CHD8 mutations present with typical autistic behaviors and comorbidities including social deficits and communication difficulties, repetitive behaviors and interests, and cognitive delays [8, 13]. However, the findings from existing studies in model organisms have not provided a clear mechanistic link between genetic defects and clinical presentations [13, 21, 22, 25, 35, 39]. One of the notable features in some of the patients with CHD8 mutations is relatively enlarged brain (macrocephaly) . This feature is consistent with the findings of enlarged brains in a sub-set of idiopathic ASD cases during early postnatal brain development. Germline mutations of Chd8 in zebrafish and mice have recapitulated the feature of enlarged brain size [13, 21, 22, 25, 35]. Accordingly, increased proliferation of neuronal progenitor cells and dysregulation of expression cell cycle genes are associated with germline line Chd8 mutation . Whether this is the underlying mechanism for macrocephaly associated with CHD8 mutations and whether it is generalizable to the macrocephaly in other idiopathic ASD cases remain to be investigated. Notably, massive apoptosis is observed in E5.5 embryos carrying germline Chd8 homozygous mutation  and somatic knockdown of Chd8 by RNAi using in utero electroporation results in a decrease proliferation of neural progenitors . These observations may indicate a different role of CHD8 at different developmental stages. More importantly, a critical question for future investigation is whether the cellular defects and enlarged brain size are responsible for ASD-like behaviors observed in Chd8 heterozygous mutant animals.
In summary, CHD8 protein is highly enriched in neurons of developing neocortex in both human and mice and plays a critical role in regulating neuronal migration as well as growth of neurites. Our findings suggest that CHD8 mutations in humans may also result in defects of neuronal migration and morphogenesis defects during a crucial stage of brain development and this impaired process may contribute to the pathophysiology of ASD.
Autism spectrum disorder
Chromodomain helicase DNA-binding protein 8
Human CHD8 protein
In utero electroporation
Quantitative real-time RNA
The ventricular zone
Miles JH. Autism spectrum disorders--a genetics review. Genet Med. 2011;13(4):278–94.
Watts TJ. The pathogenesis of autism. Clin Med Pathol. 2008;1:99–103.
O'Roak BJ, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.
Iossifov I, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74(2):285–99.
Michaelson JJ, et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell. 2012;151(7):1431–42.
Neale BM, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485(7397):242–5.
Sanders SJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485(7397):237–41.
O'Roak BJ, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485(7397):246–50.
Jiang YH, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet. 2013;93(2):249–63.
De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515(7526):209–15.
Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21.
Krumm N, et al. Excess of rare, inherited truncating mutations in autism. Nat Genet. 2015;47(6):582–8.
Bernier R, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell. 2014;158(2):263–76.
O'Roak BJ, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338(6114):1619–22.
Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat Res. 2007;618(1–2):30–40.
Okerlund ND, Cheyette BN. Synaptic Wnt signaling - a contributor to major psychiatric disorders? J Neurodev Disord. 2011;3(2):162–74.
Sakamoto I, et al. A novel beta-catenin-binding protein inhibits beta-catenin-dependent Tcf activation and axis formation. J Biol Chem. 2000;275(42):32871–8.
Durak O, et al. Chd8 mediates cortical neurogenesis via transcriptional regulation of cell cycle and Wnt signaling. Nat Neurosci. 2016;19(11):1477–88.
Nishiyama M, et al. CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. Nat Cell Biol. 2009;11(2):172–82.
Nishiyama M, et al. Early embryonic death in mice lacking the beta-catenin-binding protein Duplin. Mol Cell Biol. 2004;24(19):8386–94.
Katayama Y, et al. CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature. 2016;537(7622):675–9.
Platt RJ, et al. Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. Cell Rep. 2017;19(2):335–50.
Suetterlin P, et al. Altered neocortical gene expression, brain overgrowth and functional over-connectivity in Chd8 haploinsufficient mice. Cereb Cortex. 2018;28(6):2192–206.
Jung H, et al. Sexually dimorphic behavior, neuronal activity, and gene expression in Chd8-mutant mice. Nat Neurosci. 2018;21(9):1218–28.
Zhao C, et al. Dual requirement of CHD8 for chromatin landscape establishment and histone methyltransferase recruitment to promote CNS myelination and repair. Dev Cell. 2018;45(6):753–68 e8.
Guo SL, et al. Serum inducible kinase is a positive regulator of cortical dendrite development and is required for BDNF-promoted dendritic arborization. Cell Res. 2012;22(2):387–98.
Miao S, et al. The Angelman syndrome protein Ube3a is required for polarized dendrite morphogenesis in pyramidal neurons. J Neurosci. 2013;33(1):327–33.
Li S, et al. TORC1 regulates activity-dependent CREB-target gene transcription and dendritic growth of developing cortical neurons. J Neurosci. 2009;29(8):2334–43.
Anagnostou E, Taylor MJ. Review of neuroimaging in autism spectrum disorders: what have we learned and where we go from here. Mol Autism. 2011;2(1):4.
Di Martino A, et al. The autism brain imaging data exchange: towards a large-scale evaluation of the intrinsic brain architecture in autism. Mol Psychiatry. 2014;19(6):659–67.
Penzes P, et al. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14(3):285–93.
Hulbert SW, Jiang YH. Cellular and circuitry bases of autism: lessons learned from the temporospatial manipulation of autism genes in the brain. Neurosci Bull. 2017;33(2):205–18.
Hulbert JC, Henson RN, Anderson MC. Inducing amnesia through systemic suppression. Nat Commun. 2016;7:11003.
Jeremy Willsey A, State MW. Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol. 2015;30C:92–9.
Gompers AL, et al. Germline Chd8 haploinsufficiency alters brain development in mouse. Nat Neurosci. 2017;20(8):1062–73.
Wang P, et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in neurodevelopment. Mol Autism. 2015;6:55.
Sugathan A, et al. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. Proc Natl Acad Sci U S A. 2014;111(42):E4468–77.
de la Torre-Ubieta L, et al. The dynamic landscape of open chromatin during human cortical neurogenesis. Cell. 2018;172(1–2):289–304 e18.
Wang P, et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in cerebral organoids derived from iPS cells. Mol Autism. 2017;8:11.
This work was supported by the National Science Foundation of China [81701496 to QX, 81371270 to XX]; Shanghai Municipal Science and Technology Commission [15411967900 to QX]; and the National Institute of Health [MH098114, HD087795, MH104316 to YHJ].
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Animals: The use of mice was in accordance with guidelines and Institutional Animal Care and Use Committee-approved protocols both at Children’s Hospital of Fudan University ethics approval ID: 2015-87 and Duke University.
Human postmortem brain tissues: The use of archived human postmortem brain tissues is approved by Institute Review Board at Duke University.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Xu, Q., Liu, Yy., Wang, X. et al. Autism-associated CHD8 deficiency impairs axon development and migration of cortical neurons. Molecular Autism 9, 65 (2018). https://doi.org/10.1186/s13229-018-0244-2
- Autism spectrum disorder (ASD)
- Chromatin remodeling
- Neurite growth